FORT LAUDERDALE, FL--(Marketwire - May 22, 2012) - Imaging Diagnostic Systems, Inc. (OTCBB: IMDS), a pioneer in laser breast imaging, announced today that it has signed a distribution agreement with Mareen Group to market and sell its Computed Tomography Laser Mammography (CTLM®) System in Kuwait.
"Mareen Group is honored to present the CTLM® to the women of Kuwait. We are eager to support the imaging needs of patients through this dignified and innovative laser breast imaging modality," commented Ahmad Abdulrahman, General Manager of Mareen Group.
Mareen Group is a Medical & Pharmaceutical distribution company well established and based in Kuwait. They have been in operation since 1998, proudly providing various medical and healthcare institutions within Kuwait and the surrounding areas with advanced medical equipment and pharmaceuticals from across the globe. The philosophy of Mareen Group has always been to build close ties with their customers by supporting their every need with prompt professional service and support.
Imaging Diagnostic's CEO, Linda Grable, states, "IDSI is delighted to assign Mareen Group, a well established medical company in Kuwait, as our new distributor. The women in Kuwait will hopefully benefit from CTLM®'s unique and discrete breast imaging process to aid in the diagnosis and management of breast abnormalities. We are enthusiastic to work with Mareen Group to make the CTLM®, a non-invasive alternative, accessible to women in Kuwait."
About Imaging Diagnostic Systems, Inc.
Imaging Diagnostic Systems, Inc. is the developer of the CTLM system; a revolutionary optical breast imaging device. Optical mammography is a diffuse optical imaging technique (DOT) that aims at detecting breast cancer. The CTLM® system utilizes patented continuous wave laser technology and computed algorithms to create 3-D images of the breast. The procedure is non-invasive, painless, and does not expose the patient to ionizing radiation or painful breast compression. The CTLM® system has received certification and licenses to sell internationally through the following approvals: European CE marking, Health Canada, China SFDA, UL, ISO 13485:2003 and FDA export certification. Pending Mexico COFEPRIS and Russian GOST-R.
For more information, visit our website: www.imds.com
As contemplated by the provisions of the Safe Harbor section of the Private Securities Litigation Reform Act of 1995, this news release may contain forward-looking statements pertaining to future, anticipated, or projected plans, performances and developments, as well as other statements relating to future operations. All such forward-looking statements are necessarily only estimates or predictions of future results or events and there can be no assurance that actual results or events will not materially differ from expectations. Further information on potential factors that could affect Imaging Diagnostic Systems, Inc. is included in the Company's filings with the Securities and Exchange Commission. We expressly disclaim any intent or obligation to update any forward-looking statements.